Clinical trials: Residual Disease
Multiple Myeloma
Monitoring of Deep of Response During Lenalidomide Maintenance in MM Patients Achieving at Least Very Good Partial Response (MRD)
This is an italian multicenter study to determine whether maintenance treatment with Lenalidomide-based regimen significantly increases the rate of molecular remission in patients achieving at least a VGPR after therapy with new…
- Trial name
- MRD (NCT03433365)
- Testing
- MRD analysis
- Where
- Italy
- Volunteers
- 70 people
- Sponsor
- Fondazione EMN Italy Onlus
Sleep Apnea
Spanish Registry of Patients With Sleep Apnea and Daytime Sleepiness
Multicenter, observational and prospective study, in which patients referred to the sleep unit with suspected apnea will be recruited obstructive sleep.
- Trial name
- HYPNOSA (NCT06514482)
- Testing
- Diagnosis
- Where
- Spain
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Hospital San Pedro de Logroño
Lung Cancer, Non Small Cell Lung Carcinoma
Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy
The trial investigates the feasibility and efficacy of targeting Non-Small Cell Lung Cancer (NSCLC) "driven" by epigenetic changes.
- Conditions
- Lung Cancer, Non Small Cell Lung Carcinoma, Hypermethylation
- Trial name
- NCT01209520
- Testing
- Cisplatin, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Miami
High Grade Glioma, Glioma
5-Aminolevulinic Acid (5-ALA) Gliolan®: Usage Increase Proposal for Neurosurgical Procedures in High-Grade Gliomas
The goal of this observational study is to evaluate disease-free survival (DFS) in patients with malignant gliomas undergoing neurosurgical procedures using 5-aminolevulinic acid (5-ALA)-based photodynamic therapy
- Conditions
- High Grade Glioma, Glioma, Glioma, Malignant, Neoplasms, Neuroepithelial
- Trial name
- NCT05850377
- Testing
- 5-Aminolevulinic Acid (5-ALA) Gliolan®, Fluorescence-Guided Surgery using 5-aminolevulinic acid (5-ALA)
- Where
- Ecuador
- Volunteers
- 90 people
- Sponsor
- Sociedad de Lucha Contra el Cáncer del Ecuador
Acute Lymphoblastic Leukemia
LAL-BR/2001: Study Treatment to Low Risk ALL
The purpose of this study is increase the efficacy of consolidation (C1) after an intensification phase with high dose of methotrexate, applying analysis of minimal residual disease
- Trial name
- NCT00526175
- Testing
- Prednisone, Vincristine, Daunorubicin
- Where
- 25 sites in Spain
- Volunteers
- 150 people
- Sponsor
- PETHEMA Foundation
Colorectal Adenocarcinoma, Stage I Colorectal Cancer AJCC v8
Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study
This study investigates if circulating tumor DNA (ctDNA) and other tumor-related molecules/chemicals released in the blood can help doctors predict if colorectal cancer may come back or spread.
- Conditions
- Colorectal Adenocarcinoma, Stage I Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage IIA Colorectal Cancer AJCC v8
- Trial name
- NCT04739072
- Testing
- Biospecimen Collection, Electronic Health Record Review
- Where
- 10 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Cancer
WT1 for the Detection of Minimal Residual Disease
The purpose of this study is to determine if WT1 is an adequate measurement of minimal residual disease in leukemic patients.
- Trial name
- NCT00179829
- Testing
- WT 1 Testing
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Breast Cancer, Breast Neoplasms
Tirzepatide Weight Loss for MRD+ Early Breast Cancer
This trial aims to asses if tirzepatide-induced weight loss will lead to metabolic and hormonal changes in hormone receptor-positive (HR+), human epidermal growth factor receptor-negative (HER2-), node-positive (N+) high risk…
- Conditions
- Breast Cancer, Breast Neoplasms, Breast Cancers
- Trial name
- TRIM-EBC (NCT06517212)
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Baylor Research Institute
Chronic Myeloid Leukemia
Nilotinib Plus Pegylated Interferon-α2b in CML
The purpose of this trial is to assess the effect of switching CML patients, who have been treated with imatinib ≥ 2 years and who have stable detectable molecular residual disease between 0.01-1.0% (IS), to the combination of…
- Trial name
- NCT01866553
- Testing
- Nilotinib, Pegylated interferon α-2b
- Where
- 5 sites in Denmark, Finland and 3 more
- Volunteers
- 20 people
- Sponsor
- Amsterdam UMC, location VUmc
Precursor Lymphoid Neoplasms
Personalized Therapy of Precursor Lymphoid Neoplasms
The primary goal of this study by The Polish Adult Leukemia Group (PALG) is to verify if individual therapeutic approach taking into account biological and phenotypic differences as well as response at the level of minimal…
- Trial name
- NCT01665001
- Testing
- Treatment strategy: induction, consolidation, HSCT, maintenance
- Where
- Poland
- Volunteers
- 200 people
- Sponsor
- Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice
Lymphoma, B-Cell, Leukemia, B-Cell
CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation
The main purpose of this study is to explore the efficacy of CD19-targeted CAR-T cell therapy for minimal residual disease (MRD) in B-cell Malignancies after autologous stem cell transplantation.
- Conditions
- Lymphoma, B-Cell, Leukemia, B-Cell, Minimal Disease, Residual
- Trial name
- NCT03564977
- Testing
- CD19-targeted CAR-T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Qingdao Central Hospital
Refractory Schizophrenia
An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults
This is an adaptive, Phase II/III study in 2 parts (i.e. Part 1 (dose ranging) and Part 2 (Hypothesis testing)). NaBen® is granted Breakthrough Therapy Designation by US FDA as treatment for refractory schizophrenia.
- Trial name
- NCT03094429
- Testing
- NaBen®
- Where
- United States
- Volunteers
- 287 people
- Sponsor
- SyneuRx International (Taiwan) Corp
Gastrointestinal Stromal Tumor
Imatinib Mesylate With or Without Surgery in Treating Patients With Metastatic Gastrointestinal Stromal Tumor That is Responding to Imatinib Mesylate
RATIONALE: Surgery may remove residual disease in patients with gastrointestinal stromal tumor that is responding to imatinib mesylate.
- Trial name
- NCT00956072
- Testing
- imatinib mesylate, therapeutic conventional surgery
- Where
- Italy
- Volunteers
- 12 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Type 2 Diabetes Mellitus (DM), Gastric Ultrasound
Preoperative Gastric Volume and High-Risk Gastric Content in Patients With Type 2 Diabetes Mellitus
This prospective observational study will evaluate adult patients with type 2 diabetes mellitus who are scheduled for elective surgery.
- Trial name
- NCT07842757
- Testing
- Preoperative Gastric Ultrasonography, Capillary Fasting Blood Glucose Measurement
- Where
- Turkey (Türkiye)
- Volunteers
- 120 people
- Sponsor
- Bakirkoy Dr. Sadi Konuk Research and Training Hospital
Minimal Residual Disease, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes
Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant
This phase I/II trial studies the side effects and best dose of donor lymphocyte infusions when given together with daratumumab and to see how well they work in treating participants with acute myeloid leukemia that has come back…
- Conditions
- Minimal Residual Disease, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia
- Trial name
- NCT03537599
- Testing
- Daratumumab, Donor Lymphocyte Infusion, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Sumithira Vasu
Acute Lymphoblastic Leukemia
Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults
After consolidation therapy adult patients (≥18 yr) with Ph-negative ALL will be treated with continuation chemotherapy or allogeneic hematopoietic stem cell transplantation (alloHSCT) according to both measurable residual…
- Trial name
- NCT04179929
- Testing
- Pediatric-type of chemotherapy, allogeneic HSCT
- Where
- 108 sites in Spain
- Volunteers
- 300 people
- Sponsor
- PETHEMA Foundation
Lung Cancer
CLEAR-Lung III: Circulating Tumor DNA-Guided Consolidation Chemotherapy and Immunotherapy
CLEAR LUNG-III is a single-arm, phase II study evaluating a circulating tumor DNA (ctDNA)-guided treatment strategy in patients with unresectable stage III non-small cell lung cancer who have completed definitive chemoradiation…
- Trial name
- NCT07858253
- Testing
- Consolidation Chemotherapy
- Volunteers
- 43 people
- Sponsor
- Anusha Chidharla, MD
Medulloblastoma, Medulloblastoma, Childhood
Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease
This is a Phase 1/Phase 2 study assessing liothyronine (L-T3) immunotherapy and in combination with standard chemotherapy (bevacizumab, irinotecan and temozolomide (BIT)) in children and young adults with medulloblastoma that is…
- Conditions
- Medulloblastoma, Medulloblastoma, Childhood, Medulloblastoma Recurrent
- Trial name
- PNOC044 (NCT07346157)
- Testing
- Liothyronine (L-T3), Bevacizumab, Irinotecan
- Where
- 3 sites in United States
- Volunteers
- 69 people
- Sponsor
- Sabine Mueller, MD, PhD
Colo-rectal Cancer
A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)
The NSABP FC-13 study is being done to determine if using immunotherapies alone or in combination with other drugs will delay or prevent colorectal cancer from coming back in patients with colorectal cancer who are ctDNA-positive…
- Trial name
- EMPIRE (NCT07058012)
- Testing
- Cemiplimab, cemiplimab plus fianlimab, cemiplimab + REGN7075
- Where
- 13 sites in United States
- Volunteers
- 79 people
- Sponsor
- NSABP Foundation Inc
Tinnitus
Tinnitus Related Cerebral Activities
The proposed research is to identify the brain areas activated or deactivated by tinnitus in humans. The identification of these areas is expected to be able to treat tinnitus refractory to traditional therapies by methods of…
- Trial name
- ACCELA (NCT02853812)
- Testing
- Functional brain MRI
- Volunteers
- 24 people
- Sponsor
- University Hospital, Montpellier
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.